Clinical trials

The connection between people with genetically defined diseases and our therapies may be the most important connection we make.

Before investigational medicines can be made broadly available, the U.S. Food and Drug Administration (FDA) and other health authorities around the world require that they are studied in clinical trials.

Participating in
clinical research

Clinical trials are research studies that are designed to determine if a medicine is safe and effective for patients. Throughout the process, the safety of people participating in our clinical studies is of utmost importance to us, and many safeguards are in place.

People who choose to participate in clinical trials play a critical role in developing new medicines, particularly for rare diseases and conditions that are especially difficult to treat.

Our ongoing clinical trials are listed below.

Clinical Trials

Pyruvate Kinase Deficiency
Thalassemia
Sickle Cell Disease

Pyruvate Kinase Deficiency

Program

Study Phase

Status

Mitapivat

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Array
Mitapivat

ACTIVATE-kids

Array
Mitapivat

ACTIVATE-kidsT

Array
Mitapivat

Phase 2 DRIVE PK Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Array

Pyruvate Kinase Deficiency Global Longitudinal Registry (PEAK Registry)

Array

Thalassemia

Program

Study Phase

Status

Mitapivat

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion Dependent Alpha- or Beta-Thalassemia (ENERGIZE)

Array
Mitapivat

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

Array
Mitapivat

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Array

Sickle Cell Disease

Program

Study Phase

Status

Mitapivat

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Array
AG-946

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Array

The safety and efficacy of the agents and uses under investigation have not been established.

There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Clinical trials are the most appropriate and most common way for people to access medicines before they are approved by local health authorities.

At this time, Agios does not have an expanded access program in place to provide access to our investigational medicines outside of our clinical programs, as the benefit/risk profile is still being evaluated.

Meet Dr. Sarah Gheuens, Agios Chief Medical Officer

Our Chief Medical Officer, Sarah Gheuens, M.D., Ph.D., was a guest on Cheat Codes: A Sickle Cell Podcast. In this episode, she shares more about her background, the clinical development process, and Agios’ approach to partnering with patient communities.

Tune In

A pipeline of possibility

Our unique understanding of cellular metabolism is foundational to our success and the connective thread that binds our people and our pipeline together.

View Our Pipeline